Search

Displaying results 2241 - 2250 of 10000 in total
  1. Drug

    AER001

    go.drugbank.com/drugs/DB05078
    Investigational

    AER001, an IL4/13 receptor antagonist for severe asthma and eczema currently in Phase 2 studies.

  2. Drug

    JB991

    go.drugbank.com/drugs/DB05081
    Experimental

    JB991 is a cyclopentenone prostaglandin analogue intended for treatment of psoriasis. … In addition a closely related cyclopentenone prostaglandin analogue has been shown to exert marked anti-inflammatory effect in vivo in an animal model. The drug will be applied topically on the skin.

  3. Drug

    ARX201

    go.drugbank.com/drugs/DB05082
    Investigational

    ARX201 (PEG-ahGH) is a recombinant form of human growth hormone that has been modified using Ambrx’s patented ReCODE™ technology to achieve precise spatial positioning of the site of polyethylene glycol … (PEG) attachment to human growth hormone, by biosynthetic incorporation of a chemically unique amino acid (ahGH).

  4. Drug

    Tetrathiomolybdate

    go.drugbank.com/drugs/DB05088
    Investigational

    Tetrathiomolybdate is an oral, small-molecule, anticopper agent that is highly specific for lowering the levels of free copper in serum. … It is also developed for fibrotic disorders based upon the rationale that the fibrotic disease process is dependent upon the availability of free copper in the body.

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    M0002

    go.drugbank.com/drugs/DB05091
    Investigational

    It is a vasopressin 2 antagonist and represents a new class of compounds – aquaretics – that produce profound diuresis without loss of electrolytes. … M0002 is an orally-active selective vasopressin antagonist that inhibits water re-absorption from the kidneys.

  6. Drug

    UCB-1184197

    go.drugbank.com/drugs/DB05092
    Investigational

    Sclerosis (MS). … (now UCB S.A.) and is a putative new drug for oral treatment of multiple sclerosis.

    Categories: Heterocyclic Compounds, 2-Ring
  7. Drug

    Cimicoxib

    go.drugbank.com/drugs/DB05095
    Investigational

    Cimicoxib is a selective COX-2 inhibitor being developed by Affectis as a treatment for depression and schizophrenia. … If approved, Cimicoxib would be the first drug in decades to treat depression by a new mechanism of action.

    Categories: Heterocyclic Compounds, 1-Ring, Selective Cyclooxygenase 2 Inhibitors (NSAIDs)
  8. Drug

    Pomaglumetad methionil

    go.drugbank.com/drugs/DB05096
    Investigational

    LY2140023 is an investigational drug from Lilly, which is being developed as a new treatment option for schizophrenia. … LY2140023 is an oral "prodrug," meaning it is devoid of intrinsic biological activity and, once administered, is metabolized to provide the active mGlu2/3 receptor agonist called LY404039.

  9. Drug

    Labetuzumab

    go.drugbank.com/drugs/DB05097
    Investigational

    Labetuzumab is a humanized monoclonal antibody to carcinoembryonic antigen that inhibits tumor growth. It is used in radioimmunotherapy.

  10. Drug

    AN-9

    go.drugbank.com/drugs/DB05103
    Investigational

    Pivaloyloxymethyl butyrate (AN-9), an acyloxyalkyl ester prodrug of butyric acid (BA), exhibited low toxicity and significant anticancer activity in vitro and in vivo.

    Synonyms: AN-9